861640-76-8Relevant academic research and scientific papers
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13)
Kim, Soong-Hoon,Pudzianowski, Andrew T.,Leavitt, Kenneth J.,Barbosa, Joseph,McDonnell, Patricia A.,Metzler, William J.,Rankin, Bruce M.,Liu, Richard,Vaccaro, Wayne,Pitts, William
, p. 1101 - 1106 (2005)
Computer aided drug design led to a new class of spiro-barbiturates (e.g., 4a, MMP-13 Ki = 4.7 nM) that are potent inhibitors of MMP-13.
Bruton's tyrosine protein kinase inhibitor
-
Paragraph 0128; 0131-0133; 0142; 0146-0147; 0156; 0160-0161, (2021/10/27)
The invention discloses a compound capable of reversibly inhibiting Bruton's tyrosine protein kinase (BTK) and a pharmaceutically acceptable salt thereof, and containing the compound or a pharmaceutical composition thereof. The invention further discloses the compound or a salt and thereof, and the pharmaceutical composition is used for treating tumors caused BTK abnormity. Use of an autoimmune disease and inflammatory disease or the like.
PROCESS FOR PRODUCING PURINONE DERIVATIVE
-
Paragraph 0057; 0058; 0086; 0087, (2018/04/13)
According to the present invention, differently from well-known production methods, with the use of a different starting material, Ullmann condensation which may decrease the yield with an increase of a production scale can be avoided and thus 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one can be provided safely and stably with high reaction yield.
